An Evaluation Of Arcellx Inc (NASDAQ: ACLX) Prospects

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Arcellx Inc (ACLX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$1.47, or -2.79%, to $51.15. The Arcellx Inc has recorded 8,304 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP.

Stocks Info

ACLX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $52.62 and fluctuated between $56.09 as its day high and $51.38 as its day low. The current market capitalization of Arcellx Inc is $2.56B. A total of 0.74 million shares were traded on the day, compared to an average of 573.31K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, ACLX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 34 BUYs and 39 SELLs from insiders. Insiders purchased 274,645 shares during that period but sold 9,898,509.

In the most recent transaction, Heery Christopher sold 3,000 shares of ACLX for 35.38 per share on Aug 04. After the transaction, the Chief Medical Officer now owns 7,795 company shares. In a previous transaction on Jul 03, Heery Christopher sold 3,000 shares at 31.75 per share. ACLX shares that Chief Medical Officer owns now total 7,795.

Among the insiders who sold shares, Carroll Jill disposed of 25,556 shares on Jun 01 at a per-share price of $44.35. This resulted in the Director holding 2,487,674 shares of ACLX after the transaction. In another insider transaction, Carroll Jill sold 315,164 shares at $41.50 per share on May 31. Company shares held by the Director now total 2,513,230.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ACLX in the last 3 months, the mean price target is $60.09 with high estimates of $70.00 and low estimates of $49.00. In terms of 52-week highs and lows, ACLX has a high of $55.27 and a low of $18.70.

As of this writing, ACLX has an earnings estimate of -$0.62 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.32 per share and a lower estimate of -$1.1. The company reported an EPS of -$0.5 in the last quarter, which was -61.30% lower than expectations of -$0.31.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ACLX’s latest balance sheet shows that the firm has $104.62M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was $5.47, while its Total Shareholder’s Equity was -$121.52M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACLX is Buy with a score of 4.92.